Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
← catalyst calendarNCT04644068 · readout in 281 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
702actual
Sites
68
Countries
Australia, Canada, China +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-12 | actual | When the study began enrolling |
| Primary completion | 2027-05-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-28 | estimated | The whole study's end, after follow-up |
| First posted | 2020-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ovarian Cancer
- Breast Cancer
- Pancreatic Cancer
- Prostate Cancer
- Additional Indications Below for Module 4 and 5
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Bladder Cancer
- Gastric Cancer
- Biliary Cancer
- Cervical Cancer
- Endometrial Cancer
- Small Cell Lung Cancer Only in Module 5
Interventions
- Drug: AZD5305
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: T- Dxd
- Drug: Dato-DXd
- Drug: Camizestrant
Primary outcomes
what the primary-completion date above is the date OFThe number of subjects with adverse events/serious adverse events
measured From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.
measured From first dose of study treatment until the end of Cycle 1.
Publications
- PMID 35929986 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed